Table 1. Effects of NVP-BEZ235 on proliferation of normal and neoplastic cells.* .
| Age | Serum Tryptase | NVP-BEZ235 | ||||
| Cell Type | Diagnosis** | f/m | years | (ng/ml) | KIT D816V | IC50 (µM) |
| BM MNC | ISM | f | 69 | 16.8 | + | 0.1 |
| BM MNC | ISM | m | 82 | 30.7 | + | 0.1 |
| BM MNC | ISM | f | 44 | 14.0 | + | 0.1–0.5 |
| BM MNC | ISM | f | 39 | 11.5 | + | 0.1 |
| BM MNC | SSM | f | 56 | 133.0 | + | 0.1 |
| BM MNC | ISM | m | 66 | 65.4 | + | 0.1 |
| BM MNC*** | NHL | – | – | n.d. | n.d. | >1 |
| BM MNC*** | NHL | – | – | n.d. | n.d. | >1 |
| HMC-1.1 | MCL | n.a. | n.a. | n.a. | − | 0.025 |
| HMC-1.2 | MCL | n.a. | n.a. | n.a. | + | 0.005 |
| KU812 | CML | n.a. | n.a. | n.a. | − | 0.01 |
*Proliferation was determined by measurement of 3H-thymidine uptake as described in the text.
**Diagnoses were established according to published criteria (12,13).
***Normal/reactive BM cells were obtained from patients with NHL without BM involvement.
Abbreviations: f, female; m, male; yrs, years; BM, bone marrow; MNC, mononuclear cells; ISM, indolent systemic mastocytosis; SSM, smoldering systemic mastocytosis; NHL, Non Hodgkin's Lymphoma; MCL, mast cell leukemia; CML, chronic myeloid leukemia; n.d., not determined; n.a., not applicable.